{"name":"Connect Biopharma Australia Pty Ltd","slug":"connect-biopharma-australia-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Moxifloxacin (Avelox)","genericName":"Moxifloxacin (Avelox)","slug":"moxifloxacin-avelox","indication":"Community-acquired bacterial pneumonia","status":"marketed"}]}],"pipeline":[{"name":"Moxifloxacin (Avelox)","genericName":"Moxifloxacin (Avelox)","slug":"moxifloxacin-avelox","phase":"marketed","mechanism":"Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","indications":["Community-acquired bacterial pneumonia","Acute bacterial sinusitis","Acute bacterial exacerbation of chronic bronchitis","Uncomplicated skin and soft tissue infections","Complicated skin and soft tissue infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMnNiT2FfLUdzSjByTDk3UkszTmVvNVdDRFAwanBWN3RRQ1A1elJ0XzNVazAtQmFhbm0zM3I5RmtTOXVuenpHTExiUm1iVkV1bVY3cUJYVjZhbFo2TmRvZ0pGRzBaLUFWMmIwVGlMc19kbEhqc2ViUWNKbkxpd2xudEJ5bDlrNGNObmQtalJMTzFHc1NzaTF3V2d1eG5sRmQtT29LRERFMFd0NWZTN0dod3pwQmJGVGRq?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan","headline":"Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQVJCWDA0bUM5UkphdmxMOTVRb2hrZEZUTlAwRU1XMXdVOTdSOGVEbjF2OWpTcnUyYXFGN2kxMjJzNkpiWklHMEZuUFFEWEQ3LU5QWXMwVC1Ec1VpaE5wX3NfdHotQlo5MGxQWklKN09nczhLeXdEUzRpVFdKX1Y3RWRkSHEtZmJNRVVKQS0yRHEtWmt4VW95ajN4TWJTY09ySlBkZzVFRWFhTkl5ZkhHdFlMekhOVkFQSTI5TVNuME5WUQ?oc=5","date":"2026-03-31","type":"trial","source":"Investing.com Australia","summary":"BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia","headline":"BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQSmYtdEU2am56NGJLSmp5UGJJcUZuQjNyUVFDbmFDZlUwNF9wRmN0aVhCMTZnMHZiR0lOVi1MTkJIZzNwcWxDQkE5ZFZuX0hDVkJkcl9GSWYtdE9QWUYzR1hjaGk5azdxNkpxVWZReHdLa3RsYnE2YUtzbjRHNS1PdGs3SjFDaGhLV1NqbUpCakloeG13Qi1wMDloQnJHczdULTNPckdDajF1b1FyYWZlUUNfYWVvNm5xY05PVQ?oc=5","date":"2026-03-30","type":"trial","source":"Investing.com","summary":"Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com","headline":"Connect Biopharma reports positive Phase 1 data for asthma drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNamZibTlkb2tKSGJUWUJlZTFmY21MR2xlNDN3LTlTTG1hZWZkR2tpNlZnY0V5M29UbW1adFhLV0s0bnhCcFZwMDVjMkxsVHRTZXVHak92V255VnZCUTdRU2hVYXJuSkE4TEpIVXlfal9Ub1JmS3ZqeDdwdHJCa0psWGJPc25zN1A3LTVtQ24yMHJpVFctU3NoSHM4b3BxRjV3aVFyeWVxZnFlX2R1UGxVMTRzbTY?oc=5","date":"2026-03-30","type":"pipeline","source":"Investing.com","summary":"Connect Biopharma raises $20.2 million in private placement - Investing.com","headline":"Connect Biopharma raises $20.2 million in private placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQbmlmNk0weVJsb0FVNkhjUF96dGdHNEVkellzZEtCRGxGZ1plLTVzMUtfWmM4bGJ1NUtlVVZvNTlNcXdwNzFPOWJoX1dyOC0yWmZjcWY1T3FTQ1FXcHpESUl6TzNqWFBsQXhRc2NSamRCWmtYUU5iQ2d1STdFYTVnVlNsRS13ZnlpdWdGZnFhMVZTa2lIVmV2SkRTcF9YNXRoUnpDTTNWa0hHX3JXR1dTdjFn?oc=5","date":"2026-03-30","type":"trial","source":"Investing.com","summary":"Rademikibart shows sustained efficacy in China AD trial - Investing.com","headline":"Rademikibart shows sustained efficacy in China AD trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOWHZ2US1hZl9wY0RKUmpNUUE2Y3RfNm05YTFkeWdEVmlZV2FpYlktRGVGaDdRSklrYVpWamhRa3U1R00yRkpfaG91ZHEyeTFSQ3hRM2FSSEduQ3BjWjlHeGotNDBkUkw1dkQySHN4a3JSVk1teHM1ajJFbEFiRXZVMHhSV2FkVzBFT1Bobk1CZGhOQ0gxbTlrVDJycGhNUTBMQXktSFB3OElMblRVWDlRTlRvTld0eHhaLWNJTWh3?oc=5","date":"2026-03-30","type":"trial","source":"Investing.com Australia","summary":"Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com Australia","headline":"Connect Biopharma stock jumps on positive drug trial results By Investing.com","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQbkk4RVM2cUo5VGtyaWdnc3RMSG53bUlMbEtNb2dyZHcwWEd1M3BJaGIzclhvTzFhLUJXQlJlRXpLLS15bWN5MkRWMXE4YzNxX00tZEk5ZGp2ZWtkdUduUHV0eE9wY0p0Sm5DYzZNTHd4QjdWdS1lTU5UMVo3U0tKUEl4eE5DcmhkbXhXbGRMbmxXOFN0aVJXUl9wVlRwdTJfTnMzU1hoT0VBTG4xeFA3WW1UOFJNTEJ1VEpJMmFPNlN6SDBFWXJ0bGQwN0lRaDYxX2tQZl9XOXJ6ZGp4U3Vpby1mUDhmMzFrbVMwU01ycnlWZEh3NkVMSTN6SkEyc2lzRnpKeUVFSDRRc3N1WjV1WWxKOERXSkI1cmxjVmh0VndTWjRuTmNqM095cW1Jc2pVcUFRRkU4TGFjOXN3UlBianctbUxfb1NhMWF5Z1BR?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOemhCVl9XT0huSi16WVZjTkcxMU4yR082OU9QUWRLbEgwY0lMZWo2QVo1YUJQbXd5X0ZVZ1hGajBZNFVRRUFWeHRCbnNhT0dPR1BCcFZxWVBramk5Y2tmZE94U3FISU9HYTJrcEJtanl1NHh5WkNyb2VXQV85UVFTeW0xLWM2bi1xMktoOVZKRF9UTTFrRHZuMTNVTFFreHpqc1J4Z0dtc0Y0SWc5Z0NzdWxwQjNoSUJIRURpQUFvSmE5M0JTWmE1aXdMTUR0bWZXS0RURy1DOTg4Tkk?oc=5","date":"2026-03-25","type":"deal","source":"marketscreener.com","summary":"Simcere pharmaceutical says unit to buy entire stake in target company for rmb30.8 million - marketscreener.com","headline":"Simcere pharmaceutical says unit to buy entire stake in target company for rmb30.8 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNam9pWlp3US1LU0VNOE1Rb2puZGxpam9JU1NNUl8wMGlGdU51TTdwRnEyd0xqa2M1aUVyX1hVTzQzOWdoWTZQdFVxckQzc3VpUnEtZ1VFSUNYZDQ2Ql9DbU91WFh5UEo1MTFEZFktaFl0N0lkQzVIOC1XNE96SGg2OEVxY3hMa3l0bjBoTHpJWTdDTXZYN0NDT3dhYl9NTFZoR0lTNzJNZm9yZkYxSE4xeVZkRktLalJzYXRjQk5B?oc=5","date":"2026-03-25","type":"earnings","source":"marketscreener.com","summary":"Simcere pharmaceutical posts FY profit attributable rmb1,344 million - marketscreener.com","headline":"Simcere pharmaceutical posts FY profit attributable rmb1,344 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNRm8tX1JXMmVYMm5CVng3ek9XN05LVHRTWDMzME9NMkUxbmc1LWhBQ0FWRTJsLUp1YzVnenhGX3Zta0paM3lqTXlSbGhQZ1I2TTU2eWdhSEpfSnVNV084RUR0NzlqVGpKOTdZQzRzcnBpcU5acnFGM2pLc2F1UFpLV0phTWhoQ1FuZ3FyRDBUS2tMTjZmby1iOWJPcjdDdzFBMDJLX1dyVFJuUjJJUnJDa04ya3FlcVV3X2pBSDdHMlV0MFNQR041bmhhZFVTbUVOUnJyMWU2MUpibnl1MktuUU1hOEhReW1NM3ZvMkVaeXZkZzRlWGhoLTZLUXNhZw?oc=5","date":"2025-11-18","type":"pipeline","source":"Milwaukee Journal Sentinel","summary":"Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Milwaukee Journal Sentinel","headline":"Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-01","type":"earnings","source":"simplywall.st","summary":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Shift From Loss To Profit - simplywall.st","headline":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Shift From Loss To Profit","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}